Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
Completed · Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Bortezomib may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have untreated or relapsed Waldenstrom's macroglobulinemia.
Key facts
- Study ID
- NCT00045695
- Run by
- NCIC Clinical Trials Group
- People needed
- 27
- Starts
- 2002-08-01
- Expected to finish
- 2009-12-01
- Last updated by the study team
- 2013-05-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hinsdale Hematology Oncology Associates — Hinsdale, Illinois, United States
- Abramson Cancer Center at the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- Tom Baker Cancer Centre - Calgary — Calgary, Alberta, Canada
- Cross Cancer Institute — Edmonton, Alberta, Canada
- CancerCare Manitoba — Winnipeg, Manitoba, Canada
- Nova Scotia Cancer Centre at Queen Elizabeth II Health Sciences Centre — Halifax, Nova Scotia, Canada
- Margaret and Charles Juravinski Cancer Centre — Hamilton, Ontario, Canada
- Cancer Care Ontario-London Regional Cancer Centre — London, Ontario, Canada
- Toronto Sunnybrook Regional Cancer Centre — Toronto, Ontario, Canada
- Princess Margaret Hospital — Toronto, Ontario, Canada
- Maisonneuve-Rosemont Hospital — Montreal, Quebec, Canada
- Saskatoon Cancer Centre — Saskatoon, Saskatchewan, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.